Pharma News

Lupin has received tentative U.S. FDA approval for its oral multiple-sclerosis treatment, reinforcing its growing footprint in complex generic neurology products.

Vertex Pharmaceuticals announced encouraging new data showing that its gene-editing therapy demonstrated strong efficacy in younger pediatric patients with inherited blood disorders, further expanding the drug’s long-term commercial horizon.

Eli Lilly achieved a major market access milestone after Mounjaro was officially added to China’s national medical insurance list for diabetes treatment, dramatically improving affordability and penetration prospects across the country.

Structure-based drug developer Structure Therapeutics has reported that its experimental oral obesity therapy delivered up to 11% weight loss in a mid-stage clinical study, placing it among the most competitive non-injectable candidates in development.

The global obesity drug race has entered a new competitive phase as Wegovy’s momentum softens following multiple price reductions, while Mounjaro continues to dominate prescription rankings.

In a landmark regulatory first, the U.S. FDA has qualified its first artificial-intelligence tool designed to accelerate liver-disease drug development, validating AI as an official decision-support instrument in pharmaceutical research.

India’s deteriorating air quality has triggered a sharp rise in respiratory medicine consumption, with sales of asthma, COPD, and allergy drugs spiking strongly in November.

The U.S. Food and Drug Administration has launched a fresh safety scrutiny of newly approved RSV therapies for infants, signaling heightened regulatory caution as real-world usage expands.

Zydus Lifesciences has taken a major step into the global oncology biosimilar battlefield after announcing it will commercialize Formycon AG’s biosimilar version of Keytruda in the United States and Canada, marking one of the most strategically important

AstraZeneca recently announced plans to invest $2 billion to expand its long-term manufacturing footprint in Maryland.

• AstraZeneca

The biopharmaceutical industry rarely witnesses a moment in which capital, strategy, and organizational reform converge so clearly as in Pfizer’s recent actions.

India’s diabetes landscape is undergoing a dramatic transformation with the rapid rise of GLP-1 receptor agonists, a class of medicines that harness the body’s gut hormones to regulate blood sugar and improve overall metabolic health.

Merck is approaching the final stages of a major acquisition of Cidara Therapeutics, positioning itself to expand its influence in the global fight against influenza.

India’s pharmaceutical sector is facing a wave of uncertainty as the national regulator intensifies quality inspections across manufacturing plants.

Sun Pharma’s investigational GLP-1 receptor agonist Utreglutide has produced remarkable early-stage clinical results, offering encouraging signs for patients struggling with obesity and metabolic disorders.

Biocon Ltd is actively exploring the possibility of merging its biosimilars subsidiary, Biocon Biologics, with the parent company in a move that could value the transaction at up to $4.5 billion.

U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur, a long-time oncology expert, as the director of its Center for Drug Evaluation and Research (CDER).

Novo Nordisk’s recent announcement of cutting approximately 9,000 jobs globally, representing about 11.5% of its workforce, stands out as a defining instance of strategic contraction paired with resource concentration.

Strides Pharma Science posted a sharp improvement in quarterly earnings, reporting that net profit rose 82% year-on-year to ₹131.5 crore in Q2 FY25, supported by robust U.S. business performance and margin expansion.

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, accusing the companies of misusing confidential information to advance a rival obesity treatment.